Daridorexant
DrugDosing and treatment duration of QUVIVIQ as part of this observational study is at the discretion of the healthcare provider in accordance with local clinical practice and local labeling.
Other names: QUVIVIQ
NCT Number: NCT06498128
This study will investigate pregnancy, neonatal, and infant outcomes in women exposed to QUVIVIQ during pregnancy compared to women unexposed to QUVIVIQ during pregnancy.
Interested in participating?
Request Info15 year–50 year
Female
Observational
Jodha Tishon, Toronto, Ontario, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
A) Eligibility criteria for prospective pregnancies:
Inclusion criteria
Exclusion criteria
B) Eligibility criteria for retrospective pregnancies:
Inclusion criteria
Exclusion criteria
Dosing and treatment duration of QUVIVIQ as part of this observational study is at the discretion of the healthcare provider in accordance with local clinical practice and local labeling.
Other names: QUVIVIQ
Dosing and treatment duration of non-orexin receptor antagonist medications for insomnia as part of this observational study is at the discretion of the healthcare provider in accordance with local clinical practice and local labeling.
No insomnia medication was administered.
Time frame: Start of pregnancy up to 1 year of infant age
Congenital malformations will be classified according to the Metropolitan Atlanta Congenital Defects Program (MACDP) classification system. All potential major congenital malformations identified by the participant's or the infant's healthcare providers will be evaluated by a qualified, independent committee of at least 3 teratologists using all available medical records. Classification will be based upon the teratologists' adjudication, who will be blinded to participant exposure status.
Time frame: 20 weeks gestation until delivery/birth/labor
The presence of hypertension on 2 occasions at least 4 hours apart after 20 weeks gestation (in a woman with previously normal blood pressure) and proteinuria; or, in the absence of proteinuria, a new onset of hypertension accompanied by one of the following conditions: thrombocytopenia, renal insufficiency, impaired liver function, pulmonary edema, or cerebral or visual symptoms.
Time frame: 20 weeks gestation until delivery/birth/labor
High blood pressure associated with pregnancy, as diagnosed by the treating healthcare provider, i.e., elevated (systolic between 120-129 mmHg and diastolic less than 80 mmHg); Stage 1 hypertension (systolic between 130-139 mmHg or diastolic between 80-89 mmHg); or Stage 2 hypertension (systolic at least 140 mmHg or diastolic at least 90 mmHg).
Time frame: Start of pregnancy up to 37 weeks gestation
Regular contractions of the uterus resulting in changes in the cervix that start before 37 weeks of pregnancy.
Time frame: Start of pregnancy until delivery/birth/labor
Characterized by the development of carbohydrate intolerance with first onset or first recognition during pregnancy.
Time frame: Start of pregnancy until delivery/birth/labor
Any induced or voluntary fetal loss during pregnancy.
Time frame: Start of pregnancy up to 20 weeks gestation
Loss of a fetus due to natural causes at less than 20 weeks of gestation.
Time frame: 20 weeks gestation up to birth
Death of a fetus at or after 20 weeks of gestation.
Time frame: 37 weeks gestation up to 40 weeks gestation
Birth of a surviving neonate.
Time frame: Less than 34 weeks gestation up to 37 weeks gestation
Live birth prior to 37 weeks gestation: early preterm (< 34 weeks), late preterm (34-36 weeks), and early term (37-38 weeks).
Time frame: Start of pregnancy up to 1 year of infant age
Congenital malformations will be classified according to the Metropolitan Atlanta Congenital Defects Program (MACDP) classification system. All potential minor congenital malformations will be evaluated by at least 3, qualified, independent teratologists using all available medical records. Classification will be based upon the teratologists' adjudication, who will be blinded to participant exposure status.
Time frame: At birth of infant
All live births will be classified using the World Health Organization definition of birth weight, i.e., small (below the 10th percentile), appropriate (between the 10th and 90th percentile), or large (above the 90th percentile) for gestational age.
Time frame: At birth of infant
Birth weight of less than 2500 g; subclassified into very low birth weight (< 1500 g) and moderately low birth weight (1500 g to 2499 g).
Time frame: Birth of infant up to 1 year of infant age
Death of a live-born infant within the first year of life; subclassified as neonatal deaths (≤ 28 days of life) and infant deaths (29 to 365 days of life).
Time frame: Birth of infant up to 1 year of infant age
In-patient admissions for treatment of potentially life threatening illnesses among live-born infants within the first year of life.
Time frame: Birth of infant up to 1 year of infant age
World Health Organization Growth Charts (suitable for use in the US and EEA from birth to 24 months) will be applied for this study, where infant growth measurements will be used to estimate gender-specific weight-for-length percentiles (weight in kilograms, length in centimeters).
Time frame: Birth of infant up to 1 year of infant age
World Health Organization Growth Charts (suitable for use in the US and EEA from birth to 24 months) will be applied for this study, where infant growth measurements will be used to estimate gender-specific head circumference-for-age percentiles (head circumference in centimeters, age in months and years).
Time frame: Birth of infant up to 1 year of infant age
World Health Organization Growth Charts (suitable for use in the US and EEA from birth to 24 months) will be applied for this study, where infant growth measurements will be used to estimate gender-specific length-for-age percentiles (length in centimeters, age in months and years).
Time frame: Birth of infant up to 1 year of infant age
World Health Organization Growth Charts (suitable for use in the US and EEA from birth to 24 months) will be applied for this study, where infant growth measurements will be used to estimate gender-specific weight-for-age percentiles (weight in kilograms, age in months and years).
Contact information is provided by the study sponsor or research team.
Clinical Trial Information Europe
CONTACT
Clinical Trial Information USA
CONTACT
Idorsia Pharmaceuticals Ltd.
Industry
QUVIVIQ® Pregnancy Registry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07735390
Dyssomnias, Insomnia
Tainan, Taiwan
View Trial DetailsNCT07299240
Basal Ganglia Diseases, Brain Diseases
Nanjing, Jiangsu, China
View Trial DetailsNCT07191119
Acute Lymphoblastic Leukemia (ALL), Dyssomnias
Memphis, Tennessee, United States
View Trial DetailsNCT07323121
Basal Ganglia Diseases, Brain Diseases
Nanjing, Jiangsu, China
View Trial Details